The venture's focus on predicting drug resistance mutations from protein sequence alone aligns with the biomedicine sector. The Novo Nordisk Foundation Prize for Biomedicine could provide non-dilutive funding and recognition for the venture's innovative approach. The prize's geography in BioAlps also matches the venture's connections with Paris-Saclay and other European institutions.